<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800393</url>
  </required_header>
  <id_info>
    <org_study_id>TeMP 2021</org_study_id>
    <nct_id>NCT04800393</nct_id>
  </id_info>
  <brief_title>The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.</brief_title>
  <acronym>TeMP</acronym>
  <official_title>The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial (TeMP - Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow Clinical Scientific Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Negovsky Reanimatology Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Moscow Clinical Scientific Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Even decade ago it was believed that the choice method of anesthesia did not affect the&#xD;
      course of the oncological process, but recent evidence has begun to emerge that inhalation&#xD;
      anesthesia vs TIVA is associated with a higher number of adverse outcomes. Apparently, it&#xD;
      makes sense to conduct mRCT in order to assess the effect of IA on immune system in patients&#xD;
      operated on for breast cancer comprehensively. The results of that kind of RCT may finally&#xD;
      give us an answer whether the choice of anesthesia affects the immune status of patients&#xD;
      undergoing surgery for breast cancer. The evaluation of complications and long-term survival&#xD;
      will allow to recommend to use or not to use IA for this type of surgery.&#xD;
&#xD;
      Objective: The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and&#xD;
      Mortality in Patients Undergoing Breast Cancer Surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil-lymphocyte ratio</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Absolute number of neutrophils divided by the absolute number of lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil-lymphocyte ratio</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Absolute number of neutrophils divided by the absolute number of lymphocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>percentage of survival patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year</time_frame>
    <description>percentage of survival patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>percentage of survival patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>percentage disease-free patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 year</time_frame>
    <description>percentage disease-free patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>percentage disease-free patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>T cells of blood (CD3 +)</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Absolute number (х 10 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>T cells of blood (CD3 +)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>T helpers of blood (CD3 + CD4 +)</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>T helpers of blood (CD3 + CD4 +)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytotoxic T cells of blood (CD3 + CD8 +)</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytotoxic T cells of blood (CD3 + CD8 +)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +)</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>the ratio of T helper cells to cytotoxic T cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunoregulatory index of T helpers (CD3 + CD4 +) / cytotoxic T cells (CD3 + CD8 +)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>the ratio of T helper cells to cytotoxic T cells</description>
  </other_outcome>
  <other_outcome>
    <measure>B cells of blood (CD19 + CD3-)</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>B cells of blood (CD19 + CD3-)</measure>
    <time_frame>24 hour after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Natural killer cells of blood (CD3-CD16 +)</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Natural killer cells of blood (CD3-CD16 +)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Absolute number (х 10^9 /L)</description>
  </other_outcome>
  <other_outcome>
    <measure>T cells (CD3 +) + B cells (CD19 + CD3 -) + Natural killer cells (CD3-CD16 +) of blood</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>T cells (CD3 +) + B cells (CD19 + CD3 -) + Natural killer cells (CD3-CD16 +) of blood</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Phagocytosis</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Phagocytosis</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>mg/L</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>mg/L</description>
  </other_outcome>
  <other_outcome>
    <measure>IgA</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>IgA</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>IgM</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>IgM</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>IgG</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>IgG</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Complement component C3</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Complement component C3</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Complement component C4</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Complement component C4</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Matrix metallopeptidase 9</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Matrix metallopeptidase 9</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>ng/mL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Anesthesia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Inhalation anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Total intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>sevoflurane-based inhalational anesthesia during breast cancer surgery</description>
    <arm_group_label>Inhalation anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>propofol-based total intravenous anesthesia during breast cancer surgery</description>
    <arm_group_label>Total intravenous anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The age of the patients is from 45 to 74 years;&#xD;
&#xD;
          -  Primary operable breast cancer (BC) without prior chemotherapy;&#xD;
&#xD;
          -  Cytologically confirmed breast malignant tumor of IA-IIA stages (T1-2, N0, M0);&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute cerebrovascular accident (CVA) occurred in the previous 6 months;&#xD;
&#xD;
          -  Myocardial infarction (MI) occurred in the previous 6 months;&#xD;
&#xD;
          -  Acute arterial thrombosis or venous thromboembolism occurred in the previous 6 months;&#xD;
&#xD;
          -  Subarachnoid hemorrhage occurred during the previous 3 months;&#xD;
&#xD;
          -  Chronic kidney disease (CKD) stage 3B-5, chronic heart failure (CHF) stage IIB-III;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  History of cancer;&#xD;
&#xD;
          -  History of drug addiction;&#xD;
&#xD;
          -  Autoimmune diseases in history.&#xD;
&#xD;
          -  Post-randomization: withdrawal of informed consent (refusal to continue participating&#xD;
             in the study);&#xD;
&#xD;
          -  Post-randomization: surgical intervention, performed not in full (verified&#xD;
             non-resected lesions in the early p/o period, 2 weeks p/o).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerii Subbotin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow Scientific Clinical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valery Likhvantsev, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Negovsky Reanimatology Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerii Subbotin, PhD</last_name>
    <phone>+79166122504</phone>
    <email>subbotin67@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Kadantseva</last_name>
    <phone>+79168306947</phone>
    <email>kristina161093@gmail.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Moscow Clinical Scientific Center</investigator_affiliation>
    <investigator_full_name>Valerii Subbotin</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Phagocyte Cell Dysfunction</keyword>
  <keyword>Immune Suppression</keyword>
  <keyword>Inhalation anesthesia</keyword>
  <keyword>volatile anesthesia</keyword>
  <keyword>total intravenous anesthesia</keyword>
  <keyword>interleukins</keyword>
  <keyword>phagocytosis</keyword>
  <keyword>neutrophil-lymphocyte ratio</keyword>
  <keyword>natural killers</keyword>
  <keyword>oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

